ArticleACS biomaterials science & engineering2023
Cancer Therapeutic siRNA Delivery and Imaging by Nitrogen- and Neodymium-Doped Graphene Quantum Dots.
Article in ACS biomaterials science & engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Graphene Quantum Dots in Neurodegeneration: Protein Aggregation and the Microglial State as Therapeutic Targets.Nanomaterials (Basel, Switzerland) · 2026Review
- Evaluating NIR-II-Emissive Graphene Quantum Dot Biodistribution, Toxicity, and Clearance forACS applied nano materials · 2026Article
- Article
- Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy.International journal of molecular sciences · 2026Review
- Graphene Quantum Dots in Cancer Diagnostics and Therapeutics: Advances in Biosensing, Imaging, and Treatment Applications.Current medical science · 2026Review
- A comprehensive review on the capability of graphene quantum dots-based/involved platforms for the detection of inorganic ions.RSC advances · 2025Review
- Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment.Nanomedicine (London, England) · 2025Review
- Recent Advancements in Graphene Quantum Dot-Based Bioimaging and Drug Delivery Systems.MedComm · 2025Review
- One-step generation of luminescent core-shell microspheres for cell encapsulation via pulsed operation in centrifugal microfluidics.Microsystems & nanoengineering · 2025Article
- Advances in the Application of Graphene and Its Derivatives in Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Plasmonic Enhanced Nonlinear Absorption of Tris(2-aminoethyl)amine (TREN) Functional Ag, Pt, and Pd Nanoparticle-GQDs Complexes and Their Evaluation as Potential Bioimaging Applications.ACS applied bio materials · 2025Article
- Combination Diagnostics In Vivo: Dual-Mode Ultrasound/NIR Fluorescence Imaging with Neodymium- and Thulium-Doped Graphene Quantum Dots.ACS applied bio materials · 2025Article
- The nucleic acid reactions on the nanomaterials surface for biomedicine.Journal of nanobiotechnology · 2025Review
- Holistic Investigation of Graphene Quantum Dot Endocytosis.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Graphene Quantum Dots from Natural Carbon Sources for Drug and Gene Delivery in Cancer Treatment.International journal of molecular sciences · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
While small interfering RNA (siRNA) technology has become a powerful tool that can enable cancer-specific gene therapy, its translation to the clinic is still hampered by the inability of the genes alone to cell transfection, poor siRNA stability in blood, and the lack of delivery tracking capabilities. Recently, graphene quantum dots (GQDs) have emerged as a novel platform allowing targeted drug delivery and fluorescence image tracking in visible and near-infrared regions. These capabilities can aid in overcoming primary obstacles to siRNA therapeutics. Here, for the first time, we utilize biocompatible nitrogen- and neodymium-doped graphene quantum dots (NGQDs and Nd-NGQDs, respectively) for the delivery of Kirsten rat sarcoma virus (KRAS) and epidermal growth factor receptor (EGFR) siRNA effective against a variety of cancer types. GQDs loaded with siRNA noncovalently facilitate successful siRNA transfection into HeLa cells, confirmed by confocal fluorescence microscopy at biocompatible GQD concentrations of 375 μg/mL. While the GQD platform provides visible fluorescence tracking, Nd doping enables deeper-tissue near-infrared fluorescence imaging suitable for both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.